Drug intelligence / Profile preview

IMA910

Development stage: Phase 2
Lead developer: Immatics US, Inc.
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

IMA910 is a synthetic cancer vaccine composed of 13 tumor-associated peptides (TUMAPs) that are frequently over-expressed in colorectal cancer. These peptides are naturally presented on major histocompatibility complex (MHC) molecules of colorectal tumors, and the vaccine is designed to stimulate an immune response against these tumor antigens. IMA910 has been evaluated as a therapeutic cancer vaccine for patients with advanced or metastatic colorectal cancer, often in combination with immunomodulatory agents such as GM-CSF, low-dose cyclophosphamide, and topical imiquimod (a TLR7 agonist). The primary developer is immatics biotechnologies GmbH.

Other names: colorectal tumor-associated peptides vaccine ima910

Targets

MHC II (Major histocompatibility complex class II receptor)

Beyond the preview

Go deeper on IMA910.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMA910.

Explore the full profile